J&J files Ceftobiprole in Switzerland

A Johnson & Johnson unit has filed for Swiss approval to sell ceftobiprole, marketed in partnership with developer Basilea Pharmaceutical, as a treatment for diabetic foot infections. The drug already is on the Swiss fast track for possible treatment of skin and soft-tissue infections, and it's under review by regulators in the U.S., Canada, and the E.U.

- see this announcement
- read the AFX report

Related Articles:
J&J makes big cuts at Alza and Scios. Report
&J restructures pharma unit, laying off workers. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.